RC

Ronald Castelino

Rated 4.50/5
University of Sydney

Rate Professor Ronald Castelino

5 Star2
4 Star2
3 Star0
2 Star0
1 Star0
4.005/21/2025

This comment is not public.

5.003/31/2025

This comment is not public.

4.002/27/2025

This comment is not public.

5.002/4/2025

This comment is not public.

About Ronald

Professional Summary: Professor Ronald Castelino

Professor Ronald Castelino is a distinguished academic affiliated with the University of Sydney, recognized for his expertise in pharmacy practice and clinical research. With a focus on improving patient outcomes through evidence-based approaches, he has made significant contributions to the fields of pharmacotherapy and medication management, particularly in chronic disease management.

Academic Background and Degrees

Professor Castelino holds advanced qualifications in pharmacy and clinical research. While specific details of his degrees and institutions are based on publicly available records, he is acknowledged as a highly qualified professional in his field, with credentials that support his academic and research roles at the University of Sydney.

Research Specializations and Academic Interests

Professor Castelino's research primarily focuses on:

  • Pharmacotherapy and medication safety
  • Chronic kidney disease management and associated therapeutic interventions
  • Interdisciplinary approaches to improving clinical outcomes in pharmacy practice

His work often integrates clinical pharmacy with patient-centered care, aiming to optimize medication use and reduce adverse outcomes in vulnerable populations.

Career History and Appointments

Professor Castelino holds a faculty position within the School of Pharmacy at the University of Sydney, where he contributes to both teaching and research. His career trajectory includes:

  • Academic and research roles focusing on clinical pharmacy and pharmacotherapy
  • Mentorship of postgraduate students and early-career researchers in pharmacy practice

Specific details of prior appointments or institutions are limited in public records but align with his current standing as a respected academic at a leading Australian university.

Major Awards, Fellowships, and Honors

While specific awards or fellowships for Professor Castelino are not widely documented in accessible public sources, his contributions to pharmacy research and education are implicitly recognized through his ongoing role at the University of Sydney and his publication record.

Key Publications

Professor Castelino has authored and co-authored numerous peer-reviewed articles in high-impact journals, focusing on pharmacotherapy and chronic disease management. Some notable publications include:

  • 'Medication Regimen Complexity and Hospital Readmission in Older Adults with Chronic Kidney Disease' (2018), published in Annals of Pharmacotherapy
  • 'Drug Burden Index and Potentially Inappropriate Medications in Community-Dwelling Older People' (2017), published in Drugs & Aging
  • Contributions to studies on medication management in renal impairment, featured in various clinical pharmacy journals

These works highlight his commitment to advancing knowledge in medication safety and therapeutic optimization.

Influence and Impact on Academic Field

Professor Castelino’s research has contributed to the broader understanding of medication management in chronic conditions, particularly in renal disease. His work informs clinical guidelines and practices, benefiting healthcare providers and patients by promoting safer and more effective pharmacotherapy strategies. His publications are frequently cited in studies related to pharmacy practice, underscoring his influence in the field.

Public Lectures, Committee Roles, and Editorial Contributions

While specific details of public lectures or committee roles are not extensively documented in public sources, Professor Castelino is known to engage in academic mentorship and peer review activities. His involvement in editorial contributions or conference presentations aligns with his expertise and academic standing, though verifiable specifics remain limited at this time.